01 — What is it?
BPC-157 has a large animal and cell literature around gastrointestinal, vascular and tissue-repair signaling. Human evidence is sparse; a small 2025 pilot examined IV tolerability.
Database / Research Profiles / BPC-157
RESEARCH PROFILE
BPC-157
15-amino-acid peptide studied in tissue-repair models
Tissue repairPreclinical / very limited human evidence
EVIDENCE SNAPSHOTPRECLINICAL / VERY LIMITED HUMAN EVIDENCE
Animal/cell evidence dominates. The 2025 pilot involved only two people and cannot establish efficacy or general safety.
Research-first: This profile summarizes published evidence and regulatory context. It is educational reference material, not a diagnosis, treatment recommendation, or personalized dosing protocol.
02 — Research category
Tissue repair. Evidence strength is based on the availability and quality of human clinical data, not on popularity in the research-peptide market.
03 — Evidence map
Human evidence: LIMITED / NONEPreclinical evidence: YESPersonal dosing protocol: NOT PROVIDED
Animal/cell evidence dominates. The 2025 pilot involved only two people and cannot establish efficacy or general safety.
04 — Mechanism / biology
BPC-157 has a large animal and cell literature around gastrointestinal, vascular and tissue-repair signaling. Human evidence is sparse; a small 2025 pilot examined IV tolerability.
05 — Safety & limitations
Safety depends on the exact molecule, formulation, route, dose, indication and study population. Research-market products may differ in identity, purity, sterility or stability from materials used in published trials. Absence of reported adverse events in a small study does not establish long-term safety.
06 — Regulatory context
Regulatory status varies by compound and jurisdiction. Where an approved product exists, its approval applies only to specified formulations and indications. Investigational or research-market status should not be presented as equivalent to approval.